Drug intelligence / Profile preview

AuTri-C

Development stage: Preclinical
Lead developer: Sun Yat-sen University
Modality: Small Molecules
Administration: Intravenous

Overview

AuTri-C is a geometrically distinct, tri-coordinated gold(I) complex featuring an N^N-bidentate ligand and an N-heterocyclic carbene (NHC) ligand. Developed for the treatment of glioblastoma multiforme (GBM), the compound is designed to overcome the limitations of conventional therapies, such as drug resistance and poor targetability in the brain. AuTri-C acts by modulating mitochondrial morphology, leading to mitochondrial dysfunction, the accumulation of reactive oxygen species (ROS), and the subsequent induction of apoptosis in cancer cells. Preclinical studies in both in vitro and in vivo models have demonstrated its ability to inhibit GBM growth and recurrence, highlighting its potential as a novel anti-GBM therapeutic agent.

Other names: tri-coordinated gold(I) complexAu(I)-NHC complex

Beyond the preview

Go deeper on AuTri-C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AuTri-C.

Explore the full profile